Lantheus Holdings operates a high-quality specialty healthcare franchise with exceptional free cash flow conversion and a perfect financial health score, but the stock has moved above its near-term price target, leaving the risk/reward firmly negative at the current price.
Thesis pillars
- Exceptional Cash Generation Quality→Stable
- Attractive Growth Adjusted Valuation→Stable
- Consecutive Earnings Outperformance→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
Lantheus Holdings, Inc. (LNTH) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $100.80, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers (synthesis boxes, lipid blend); Analyst target reached - limited upside remaining.
Lantheus Holdings markets PYLARIFY (prostate cancer PSMA PET imaging, FDA-approved May 2021), DEFINITY (ultrasound contrast agent with estimated over 80% U.S. echocardiography segment share), and Neuraceq (Alzheimer's amyloid PET) to hospitals and imaging centers primarily in... Read more
Hold if already holding. Not a fresh buy at $100.80, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers (synthesis boxes, lipid blend); Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Maintain position. Not compelling to add more. Score 6.5/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: moderate.
About Lantheus Holdings, Inc.
About Lantheus Holdings, Inc.
Lantheus Holdings markets PYLARIFY (piflufolastat F-18, FDA-approved May 2021) for prostate PSMA PET imaging, DEFINITY ultrasound contrast with an estimated over 80% share of the U.S. echocardiography ultrasound enhancing agent segment, and Neuraceq for Alzheimer's amyloid PET imaging — acquired via Life Molecular Imaging in July 2025 for $352.9 million. On January 1, 2026, the company sold its SPECT business to SHINE Technologies for up to $155.0 million, sharpening focus on PET radiodiagnostics and microbubbles.
Lantheus earns revenue across three categories: Radiopharmaceutical Oncology (dominated by PYLARIFY), Precision Diagnostics (DEFINITY, Neuraceq), and Strategic Partnerships, which includes royalties, milestones, and CDMO revenue from Evergreen Theragnostics (acquired April 1, 2025 for $276.4 million upfront). PYLARIFY is sold to hospitals, independent imaging centers, and government facilities in the United States through an internal sales team and selected PMF partner sales teams; reimbursement shifted from ASP-plus-six-percent under expired TPT Status (through December 31, 2024) to a mean unit cost basis under the CMS 2026 OPPS Rule — paying at a lower rate than competing PSMA agents from Telix Pharmaceuticals, Novartis, and Blue Earth Diagnostics that retain TPT Status. DEFINITY relies on Jubilant HollisterStier as a substantial supplier and competes with GE Healthcare and Bracco Diagnostics. The company also purchases certain key raw materials from sole suppliers, including the specially designed synthesis boxes for PYLARIFY manufacturing and lipid blend material and perflutren gas for DEFINITY.
Show full overview
PYLARIFY's five-year new chemical entity exclusivity expires May 26, 2026, potentially opening the ANDA pathway to generic challengers under the Hatch-Waxman Act. Lantheus holds six Orange Book-listed patents for PYLARIFY, the last expiring in 2037; a timely Paragraph IV lawsuit could trigger a 30-month FDA stay potentially extending to November 2028. Separately, Lantheus submitted an NDA for a new PYLARIFY formulation with an FDA PDUFA target date of March 6, 2026 — if approved, the company plans to seek three years of renewed TPT Status from CMS, which could partially offset the reimbursement disadvantage versus agents retaining existing TPT Status.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Lantheus Holdings, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 1, 2026Recent Developments — Lantheus Holdings, Inc.
Latest news
- NEWS LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value - Stocktwits — Stocktwits Nov 1, 2026 negative
- NEWS Lantheus earnings on deck as Curium merger awaits FTC review By Investing.com - Investing.com South Africa — Investing.com South Africa Oct 28, 2026 neutral
- NEWS LNTH Q3'26 Earnings: EPS estimate is 1.26 USD - TradingView — TradingView Oct 28, 2026 neutral
- NEWS ETFs Are Selling Lantheus (LNTH) on Oct. 19 - Yahoo Finance — Yahoo Finance Oct 21, 2026 neutral
- NEWS ETFs Are Selling Lantheus (LNTH) on Oct. 19 - GuruFocus — GuruFocus Oct 21, 2026 neutral
Latest item Nov 1, 2026 · Generated 2026-11-04T11:34:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductPYLARIFY10-K Item 1A: 'Continued substantial revenue contribution from PYLARIFY is dependent on'
- MEDIUMSupplierJubilant HollisterStier10-K Item 1A: 'We rely on Jubilant HollisterStier as a substantial supplier of DEFINITY'
- HIGHSuppliersole suppliers (synthesis boxes, lipid blend)10-K Item 1A: 'we purchase certain components and raw materials from sole suppliers (including, for example, the specially designed chemistry synthesis boxes'
Material Events(8-K, last 90d)
- 2026-05-01Item 3.03LOWCharter amendment on April 30, 2026 modified rights of security holders per Item 5.03 (content truncated); related to shareholder approval of the A&R 2026 Equity Incentive Plan, which added 2,000,000 shares and changed non-employee director compensation limits.SEC filing →
- 2026-05-01Item 5.02LOWShareholders approved A&R 2026 Equity Incentive Plan on April 30, 2026: added 2,000,000 shares, changed non-employee director comp limits to $1,250,000 (appointment year) and $750,000 (subsequent years), removed certain Section 162(m) provisions.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $100.80, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers (synthesis boxes, lipid blend); Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Maintain position. Not compelling to add more. Analyst target $93.08 reached (−7.7%), stop $100.00 (−0.8%), A.R:R -0.5:1. Score 6.5/10, moderate confidence.
Analyst target $93.08 reached (−7.7% from $100.80); no take-profit level is published. Analyst target $93.08 reached (−7.7%), stop $100.00 (−0.8%), A.R:R -0.5:1. Stop-loss: $100.00.
Concentration risk — Supplier: sole suppliers (synthesis boxes, lipid blend); Analyst target reached - limited upside remaining.
Lantheus Holdings, Inc. trades at a P/E of 24.3 (forward 15.6). TrendMatrix value score: 6.3/10. Verdict: Hold.
16 analysts rate LNTH, with a consensus score of 3.6/5. 8 analysts publish price targets averaging $107.
What does Lantheus Holdings, Inc. do?Lantheus Holdings markets PYLARIFY (prostate cancer PSMA PET imaging, FDA-approved May 2021), DEFINITY (ultrasound...
Lantheus Holdings markets PYLARIFY (prostate cancer PSMA PET imaging, FDA-approved May 2021), DEFINITY (ultrasound contrast agent with estimated over 80% U.S. echocardiography segment share), and Neuraceq (Alzheimer's amyloid PET) to hospitals and imaging centers primarily in the United States. Revenue comes from product sales, royalties, milestone payments, and CDMO services.